CS1002 plus CS1003 showed promising antitumor activity and had a manageable safety profile across a broad dosing range in trials
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.